Last news
Axi Announces Retirement of Chief Commercial Officer Louis Cooper

Axi Announces Retirement of Chief Commercial Officer Louis Cooper

Notified -...

OPEC Fund mobilizes over US$1 billion to advance sustainable development

OPEC Fund mobilizes over US$1 billion to advance sustainable development

Notified -...

WHO Disenfranchises the Public from Tobacco Control Conference as Registration Barriers Reach "Insane" Levels

WHO Disenfranchises the Public from Tobacco Control Conference as Registration Barriers Reach "Insane" Levels

Notified -...

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

Notified -...

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Notified -...

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Notified -...

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Notified -...

CGTN: Nurturing 'she power': Peng Liyuan calls to empower women with science education

CGTN: Nurturing 'she power': Peng Liyuan calls to empower women with science education

Notified -...

1 ... 331 332 333 334 335 336 337 338 339 ... 1235
menu
menu